Oleclumab (10 mg/kg; ip; every 3 days for 4 doses) increases the proportion of activated CD8+ lymphocyte populations in the mouse Balb/c syngeneic CT26 colon cancer tumor model. And Oleclumab significantly inhibits tumor growth[2].
| Animal Model: | Murine, Balb/c, syngeneic CT26 colon carcinoma tumor model[2] |
| Dosage: | 10 mg/kg |
| Administration: | ip; 2 time per week, for 2 weeks |
| Result: | Inhibited tumor growth by 50% or greater from study day 7 to study day 16 when compared with isotype control antibody-treated groups.
|
